サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1347844

精密医療の世界市場：タイプ別、適応症別、エンドユーザー別、地域別-2028年までの予測

Precision Medicine Market by Type, Indication, End user & Region - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 234 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
精密医療の世界市場：タイプ別、適応症別、エンドユーザー別、地域別-2028年までの予測
出版日: 2023年09月06日
発行: MarketsandMarkets
ページ情報: 英文 234 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

精密医療の市場規模は、予測期間中にCAGR 11.5%で拡大し、2023年の291億米ドルから2028年には502億米ドルに達すると予測されています。

精密医療市場の成長を促進する主な要因としては、ゲノム研究に関連するイニシアチブの拡大、個別化治療薬に対する規制当局の承認数の増加などが挙げられます。さらに、細胞治療や遺伝子治療に対する需要の高まりは、この市場の機会領域となっています。

精密医療市場は、タイプ別に、阻害薬、モノクローナル、細胞・遺伝子治療、抗ウイルス・抗レトロウイルス薬、その他の治療製品に分類されます。2022年には、モノクローナル抗体が従来の医薬品よりも優れているなどの要因により、モノクローナル抗体が最も高い成長率を占めました。これらの利点により、臨床パイプラインの焦点はモノクローナル抗体にシフトしています。

エンドユーザー別では、精密医療市場は病院・クリニックと在宅医療環境に区分されます。2022年には、病院・診療所セグメントが精密医療市場で最大のシェアを占めました。この市場セグメントの成長は、病院での遺伝子検査、診断、カウンセリングなどのサービスが利用できることに起因しています。その上、病院は、精密医療を選択する患者のために用意された治療製品を容易に入手することができます。

北米は精密医療市場で最大のシェアを占めています。北米地域の大きなシェアは、精密医療を提供するヘルスケア環境における技術的に高度なインフラの存在や、先進的な治療薬への容易なアクセスなどの主な要因に起因しています。加えて、この地域には確立されたヘルスケアシステムがあり、これがこの市場の成長をさらに後押ししています。

欧州の精密医療市場は、予測期間中に最も高いCAGRで成長すると予測されています。これは、同市場における主要参入企業の存在と精密医療の進歩に向けたイニシアチブの高まりを含む主要因の1つによるものです。これらの参入企業の例としては、F. Hoffmann-La Roche Ltd.（スイス）、Novartis AG.（スイス）、Novartis AG（スイス）、AstraZeneca（英国）、GlaxoSmithKline plc（英国）などが挙げられます。

当レポートでは、世界の精密医療市場について調査し、タイプ別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • ポーターのファイブフォース分析
  • 技術分析
  • バリューチェーン分析
  • エコシステム分析
  • 特許分析
  • パイプライン分析
  • サプライチェーン分析
  • 規制分析
  • 価格分析
  • 顧客のビジネスに影響を与える動向/混乱
  • 主要な会議とイベント
  • 主要な利害関係者と購入基準

第6章 精密医療市場、タイプ別

  • イントロダクション
  • 阻害剤
  • モノクローナル抗体
  • 細胞および遺伝子治療
  • 抗ウイルス薬および抗レトロウイルス薬
  • その他

第7章 精密医療市場、適応症別

  • イントロダクション
  • 腫瘍学
  • 希少疾患
  • 感染症
  • 血液疾患
  • その他

第8章 精密医療市場、エンドユーザー別

  • イントロダクション
  • 病院と診療所
  • 在宅医療

第9章 精密医療市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第10章 競合情勢

第11章 企業プロファイル

  • 主要参入企業
    • F. HOFFMANN-LA ROCHE LTD.
    • BRISTOL MYERS SQUIBB
    • NOVARTIS AG
    • GILEAD SCIENCES, INC.
    • ASTRAZENECA
    • ABBVIE INC.
    • ELI LILLY AND COMPANY
    • SAREPTA THERAPEUTICS, INC.
    • PFIZER INC.
    • GLAXOSMITHKLINE PLC
    • SANOFI
    • JOHNSON & JOHNSON
    • BLUEBIRD BIO, INC.
    • MERCK KGAA
    • AMGEN, INC.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • REGENERON PHARMACEUTICALS, INC.
    • IMMUNOCORE LTD.
    • BLUEPRINT MEDICINES CORPORATION
  • その他の企業
    • VERTEX PHARMACEUTICALS INCORPORATED
    • MIRATI THERAPEUTICS, INC
    • ARGENX SE
    • HORIZON THERAPEUTICS PLC
    • BRIDGEBIO PHARMA, INC.
    • TREVENA, INC.
    • INCYTE CORPORATION
    • ALNYLAM PHARMACEUTICALS, INC.
    • RIGEL PHARMACEUTICALS, INC.
    • TAIHO PHARMACEUTICAL CO., LTD（PART OF OTSUKA HOLDINGS CO., LTD.）
    • AGIOS PHARMACEUTICALS, INC.
    • SEAGEN, INC.
    • RHYTHM PHARMACEUTICALS, INC.
    • MACROGENICS, INC.

第12章 付録

目次
Product Code: BT 8776

The precision medicine market is expected to reach USD 50.2 billion by 2028 from USD 29.1 billion in 2023, at a CAGR of 11.5% during the forecast period. The key factors driving the growth of the precision medicine market include growing initiatives related to genomic research, and increasing number of regulatory approvals for personalized therapeutics. Moreover, rising demand for cell and gene therapies is an opportunity area for this market.

The precision medicine market has been segmented based on type, indication, end user and region.

"By type, the monoclonal antibodies segment accounted for the second largest share of the precision medicine market"

Based on type, the precision medicine market is categorized into inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. In 2022, monoclonal antibodies accounted for the highest growth rate owing to factors such as benefits offered by monoclonal antibodies over traditional medicines. These advantages have led to shifting focus of the clinical pipeline dominantly on monoclonal antibodies.

"By end user, the hospitals and clinics segment accounted for the largest share in the precision medicine market"

Based on end user, the precision medicine market is segmented into hospitals and clinics and home care settings. In 2022, the hospitals and clinics segment accounted for a largest share of the precision medicine market. Growth in this market segment can be attributed to availability of services such as genetic testing, diagnostics and counselling in hospital setups. Besides, hospitals have easy accessibility of therapeutic products which are made available for patients opting for precison medicine regime.

"North America: the largest share of the precision medicine market"

North America accounted for the largest share of the precision medicine market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering precision medicines, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market.

"Europe: The fastest-growing region in the precision medicine market."

The Europe precision medicine market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for precision medicine advancements with presence of some of the key players in the market. Some examples of these players include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc (UK) among others.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
  • By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 2.5% & Africa- 2.5%

Prominent Players

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • Bristol Myers Squibb (US)
  • AstraZeneca (UK)
  • Gilead Sciences, Inc. (US)
  • AbbVie Inc. (US)
  • Eli Lilly and Company (US)
  • GlaxoSmithKline plc (UK)
  • Sanofi (France)
  • Johnson & Johnson (US)
  • Merck KGaA (Germany)
  • Amgen, Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Regeneron Pharmaceuticals, Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • bluebird bio, Inc. (US)
  • Immunocore Holdings Plc (UK)
  • Blueprint Medicines Corporation (US)
  • Vertex Pharmaceuticals Incorporated (US)
  • Horizon Therapeutics Plc (Ireland)
  • Alnylam Pharmaceuticals, Inc. (US)
  • Rigel Pharmaceuticals, Inc. (US)
  • Taiho Pharmaceutical Co., Ltd. (Japan)
  • Seagen Inc. (US)

Research Coverage:

This report provides a detailed picture of the precision medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the precision medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

  • Analysis of key drivers (growth in genomic research, genetic testing and companion diagnostics), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with precision medicines adoption) influencing the growth of the precision medicine market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the precision medicine market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the precision medicine market across varied regions.
  • Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the precision medicine market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others in the precision medicine market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 PRECISION MEDICINE MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
    • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 5 MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH FORECAST
    • FIGURE 8 PRECISION MEDICINE MARKET: CAGR PROJECTIONS
    • FIGURE 9 PRECISION MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 11 PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 PRECISION MEDICINE MARKET, BY INDICATION, 2023 VS. 2028
    • FIGURE 13 PRECISION MEDICINE MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET

4 PREMIUM INSIGHTS

  • 4.1 PRECISION MEDICINE MARKET OVERVIEW
    • FIGURE 15 INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE AND COUNTRY
    • FIGURE 16 INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA (2022)
  • 4.3 PRECISION MEDICINE MARKET, BY INDICATION
    • FIGURE 17 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 PRECISION MEDICINE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 18 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing focus on genomic research
    • TABLE 2 INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE
      • 5.2.1.2 Growth in genetic testing and companion diagnostics
      • 5.2.1.3 Increasing regulatory approvals for personalized therapeutics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs of therapeutic development
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for cell and gene therapies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Challenges associated with adoption of precision medicine
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 TECHNOLOGY ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 20 PRECISION MEDICINE MARKET: VALUE CHAIN
    • 5.5.1 RESEARCH & DEVELOPMENT
    • 5.5.2 MANUFACTURING
    • 5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 21 PRECISION MEDICINE MARKET: ECOSYSTEM MAP
  • 5.7 PATENT ANALYSIS
    • FIGURE 22 PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012-JULY 2023)
    • TABLE 4 PRECISION MEDICINE MARKET: INDICATIVE LIST OF PATENTS
  • 5.8 PIPELINE ANALYSIS
    • TABLE 5 PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE
  • 5.9 SUPPLY CHAIN ANALYSIS
    • 5.9.1 PROMINENT COMPANIES
    • 5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES
    • 5.9.3 END USERS
    • 5.9.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
    • 5.9.5 REGULATORY BODIES
    • FIGURE 23 PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
    • TABLE 6 PRECISION MEDICINE MARKET: SUPPLY CHAIN ECOSYSTEM
  • 5.10 REGULATORY ANALYSIS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PRICING ANALYSIS
    • 5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
    • TABLE 11 AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.13 KEY CONFERENCES AND EVENTS
    • TABLE 12 PRECISION MEDICINE MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023-2024)
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS
    • 5.14.2 BUYING CRITERIA FOR PRECISION MEDICINE MARKET
    • FIGURE 25 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS

6 PRECISION MEDICINE MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 13 PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2 INHIBITOR DRUGS
    • 6.2.1 ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET
    • TABLE 14 APPROVED INHIBITOR DRUGS IN PRECISION MEDICINE MARKET (2022)
    • TABLE 15 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 16 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 MONOCLONAL ANTIBODIES
    • 6.3.1 HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET
    • TABLE 19 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 CELL AND GENE THERAPY
    • 6.4.1 WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET
    • TABLE 23 PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 24 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 EUROPE: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 ANTIVIRAL AND ANTIRETROVIRAL DRUGS
    • 6.5.1 MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH
    • TABLE 27 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 OTHER THERAPEUTIC PRODUCTS
    • TABLE 31 PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)

7 PRECISION MEDICINE MARKET, BY INDICATION

  • 7.1 INTRODUCTION
    • TABLE 35 PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 7.2 ONCOLOGY
    • 7.2.1 INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET
    • TABLE 36 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 RARE DISEASES
    • 7.3.1 GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
    • TABLE 40 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 INFECTIOUS DISEASES
    • 7.4.1 RISING INCIDENCE OF HIV AND TB TO FUEL MARKET
    • TABLE 44 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 HEMATOLOGICAL DISORDERS
    • 7.5.1 INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH
    • TABLE 48 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.6 OTHER INDICATIONS
    • TABLE 52 PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 PRECISION MEDICINE MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 56 PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS AND CLINICS
    • 8.2.1 WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET
    • TABLE 57 PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 HOME CARE SETTINGS
    • 8.3.1 ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH
    • TABLE 61 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)

9 PRECISION MEDICINE MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 65 PRECISION MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 26 NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT
    • TABLE 66 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 69 NORTH AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Rising regulatory approvals for therapeutic products to drive market
    • TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA
    • TABLE 71 US: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 US: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 73 US: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Rising incidence of cancer to drive market
    • TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 75 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • FIGURE 27 EUROPE: PRECISION MEDICINE MARKET SNAPSHOT
    • TABLE 77 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 79 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Rising R&D initiatives for therapeutics to drive market
    • TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 82 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 83 GERMANY: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Rising incidence of hematologic cancers to drive market
    • TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 85 UK: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 87 UK: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Increasing initiatives in genomic research to drive market
    • TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 89 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 90 FRANCE: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Growing awareness initiatives for personalized treatment to propel market
    • TABLE 91 ITALY: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 93 ITALY: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth
    • TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 95 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 96 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 97 REST OF EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 98 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 99 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.7 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • TABLE 100 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 High incidence of chronic diseases and large patient volume to fuel market
    • TABLE 104 CHINA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 106 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Availability of reimbursements for medical procedures to support market growth
    • TABLE 107 JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 109 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Rising burden of chronic diseases to drive market
    • TABLE 110 INDIA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 112 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 Rising R&D projects for genomic sequencing to propel market
    • TABLE 113 AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 115 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 116 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 117 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 118 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 LATIN AMERICA
    • 9.5.1 INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH
    • TABLE 119 LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 121 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.5.2 LATIN AMERICA: RECESSION IMPACT
  • 9.6 MIDDLE EAST
    • 9.6.1 RISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
    • TABLE 122 MIDDLE EAST: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 MIDDLE EAST: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 124 MIDDLE EAST: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.7 AFRICA
    • 9.7.1 INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH
    • TABLE 125 AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 126 AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 127 AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.8 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
    • 10.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
  • 10.2 MARKET SHARE ANALYSIS
    • FIGURE 28 PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 128 PRECISION MEDICINE MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 10.3 REVENUE SHARE ANALYSIS
    • FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020-2022)
  • 10.4 COMPANY EVALUATION MATRIX
    • FIGURE 30 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (2022)
    • 10.4.1 STARS
    • 10.4.2 PERVASIVE PLAYERS
    • 10.4.3 EMERGING LEADERS
    • 10.4.4 PARTICIPANTS
  • 10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
    • FIGURE 31 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
    • 10.5.1 PROGRESSIVE COMPANIES
    • 10.5.2 STARTING BLOCKS
    • 10.5.3 DYNAMIC COMPANIES
    • 10.5.4 RESPONSIVE COMPANIES
  • 10.6 COMPETITIVE BENCHMARKING OF LEADING PLAYERS
    • 10.6.1 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 129 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS
    • 10.6.2 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 130 PRECISION MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS
  • 10.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
    • TABLE 131 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 132 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 10.8 COMPETITIVE SCENARIO AND TRENDS
    • 10.8.1 PRODUCT APPROVALS
    • TABLE 133 PRECISION MEDICINE MARKET: PRODUCT APPROVALS (JANUARY 2020-JUNE 2023)
    • 10.8.2 DEALS
    • TABLE 134 PRECISION MEDICINE MARKET: DEALS (JANUARY 2020-JUNE 2023)
    • 10.8.3 OTHER DEVELOPMENTS
    • TABLE 135 PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS (JANUARY 2020-JULY 2023)

11 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 11.1 KEY PLAYERS
    • 11.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 136 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
    • FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • TABLE 137 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS
    • 11.1.2 BRISTOL MYERS SQUIBB
    • TABLE 138 BRISTOL MYERS SQUIBB: COMPANY OVERVIEW
    • FIGURE 33 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022)
    • TABLE 139 BRISTOL MYERS SQUIBB: DEALS
    • TABLE 140 BRISTOL MYERS SQUIBB: PRODUCT APPROVALS
    • 11.1.3 NOVARTIS AG
    • TABLE 141 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
    • TABLE 142 NOVARTIS AG: DEALS
    • TABLE 143 NOVARTIS AG: PRODUCT APPROVALS
    • 11.1.4 GILEAD SCIENCES, INC.
    • TABLE 144 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
    • FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 145 GILEAD SCIENCES, INC.: DEALS
    • TABLE 146 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
    • 11.1.5 ASTRAZENECA
    • TABLE 147 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2022)
    • TABLE 148 ASTRAZENECA: DEALS
    • TABLE 149 ASTRAZENECA: PRODUCT APPROVALS
    • 11.1.6 ABBVIE INC.
    • TABLE 150 ABBVIE INC.: COMPANY OVERVIEW
    • FIGURE 37 ABBVIE INC.: COMPANY SNAPSHOT (2022)
    • TABLE 151 ABBVIE INC.: DEALS
    • 11.1.7 ELI LILLY AND COMPANY
    • TABLE 152 ELI LILLY AND COMPANY: COMPANY OVERVIEW
    • FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
    • TABLE 153 ELI LILLY AND COMPANY: DEALS
    • TABLE 154 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
    • 11.1.8 SAREPTA THERAPEUTICS, INC.
    • TABLE 155 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
    • FIGURE 39 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • TABLE 156 SAREPTA THERAPEUTICS, INC.: DEALS
    • TABLE 157 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
    • TABLE 158 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
    • 11.1.9 PFIZER INC.
    • TABLE 159 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 40 PFIZER INC.: COMPANY SNAPSHOT (2022)
    • TABLE 160 PFIZER INC.: DEALS
    • TABLE 161 PFIZER INC.: PRODUCT APPROVALS
    • TABLE 162 PFIZER INC.: OTHER DEVELOPMENTS
    • 11.1.10 GLAXOSMITHKLINE PLC
    • TABLE 163 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
    • FIGURE 41 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
    • TABLE 164 GLAXOSMITHKLINE PLC: DEALS
    • TABLE 165 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
    • 11.1.11 SANOFI
    • TABLE 166 SANOFI: COMPANY OVERVIEW
    • FIGURE 42 SANOFI: COMPANY SNAPSHOT (2022)
    • TABLE 167 SANOFI: DEALS
    • TABLE 168 SANOFI: PRODUCT APPROVALS
    • 11.1.12 JOHNSON & JOHNSON
    • TABLE 169 JOHNSON & JOHNSON: COMPANY OVERVIEW
    • FIGURE 43 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
    • TABLE 170 JOHNSON & JOHNSON: PRODUCT APPROVALS
    • 11.1.13 BLUEBIRD BIO, INC.
    • TABLE 171 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
    • FIGURE 44 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 172 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES
    • TABLE 173 BLUEBIRD BIO, INC.: PRODUCT APPROVALS
    • 11.1.14 MERCK KGAA
    • TABLE 174 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • TABLE 175 MERCK KGAA: PRODUCT APPROVALS
    • 11.1.15 AMGEN, INC.
    • TABLE 176 AMGEN, INC.: COMPANY OVERVIEW
    • FIGURE 46 AMGEN, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 177 AMGEN, INC.: DEALS
    • TABLE 178 AMGEN, INC.: PRODUCT APPROVALS
    • 11.1.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • TABLE 179 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
    • FIGURE 47 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
    • TABLE 180 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
    • 11.1.17 REGENERON PHARMACEUTICALS, INC.
    • TABLE 181 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 48 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 182 REGENERON PHARMACEUTICALS, INC.: DEALS
    • TABLE 183 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS
    • 11.1.18 IMMUNOCORE LTD.
    • TABLE 184 IMMUNOCORE LTD.: COMPANY OVERVIEW
    • FIGURE 49 IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022)
    • TABLE 185 IMMUNOCORE LTD.: DEALS
    • TABLE 186 IMMUNOCORE LTD.: PRODUCT APPROVALS
    • 11.1.19 BLUEPRINT MEDICINES CORPORATION
    • TABLE 187 BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022)
    • TABLE 188 BLUEPRINT MEDICINES CORPORATION: DEALS
    • TABLE 189 BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS
  • 11.2 OTHER PLAYERS
    • 11.2.1 VERTEX PHARMACEUTICALS INCORPORATED
    • 11.2.2 MIRATI THERAPEUTICS, INC
    • 11.2.3 ARGENX SE
    • 11.2.4 HORIZON THERAPEUTICS PLC
    • 11.2.5 BRIDGEBIO PHARMA, INC.
    • 11.2.6 TREVENA, INC.
    • 11.2.7 INCYTE CORPORATION
    • 11.2.8 ALNYLAM PHARMACEUTICALS, INC.
    • 11.2.9 RIGEL PHARMACEUTICALS, INC.
    • 11.2.10 TAIHO PHARMACEUTICAL CO., LTD (PART OF OTSUKA HOLDINGS CO., LTD.)
    • 11.2.11 AGIOS PHARMACEUTICALS, INC.
    • 11.2.12 SEAGEN, INC.
    • 11.2.13 RHYTHM PHARMACEUTICALS, INC.
    • 11.2.14 MACROGENICS, INC.
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS